Skip to main content
Top
Published in: Supportive Care in Cancer 7/2021

01-07-2021 | Pediatric Cancer | Original Article

Adverse childhood experiences (ACEs) and medically traumatic events (TEs) in adolescents and young adults (AYAs) with cancer: a report from the Promoting Resilience in Stress Management (PRISM) randomized controlled trial

Authors: Samantha R. Scott, Alison G. O’Daffer, Miranda C. Bradford, Kaitlyn Fladeboe, Nancy Lau, Angela Steineck, Mallory Taylor, Joyce P. Yi-Frazier, Abby R. Rosenberg

Published in: Supportive Care in Cancer | Issue 7/2021

Login to get access

Abstract

Objective

In adolescents and young adults (AYAs) with cancer, we examined (1) the distribution and type of traumatic events (TEs) experienced prior to baseline assessment and (2) how a resilience intervention, Promoting Resilience in Stress Management (PRISM), impacted changes in patient-reported outcomes (PROs) for AYAs with and without TEs.

Methods

AYAs (12–25 years) within 1–10 weeks of diagnosis of new malignancy or ever diagnosed with advanced cancer were enrolled and randomly assigned to usual care (UC) with or without PRISM. To assess TEs, we screened medical records for traditionally defined adverse childhood experiences (ACEs) and medical traumatic events. Age-validated PROs assessed resilience, benefit-finding, hope, generic health-related quality of life (QoL), cancer-specific QoL, depression, and anxiety at enrollment and 6 months later. We calculated effect sizes (Cohen’s d) for PRISM vs. UC effect on PRO score change at 6 months for 1+ TEs and 0 TE groups.

Results

Ninety-two AYAs enrolled and completed baseline surveys (44-UC, 48-PRISM; N = 74 at 6 months, 38-UC, 36-PRISM); 60% experienced 1+ TEs. PROs at baseline were similar across groups. PRISM’s effect on score change was greater (Cohen’s d ≥ 0.5) for the 1+ TE group on domains of benefit-finding and hope; and similar (d < 0.5) on domains of resilience, depression, anxiety, and both generic and cancer-specific QoL.

Conclusions

In AYAs with cancer, TEs occurred at similar rates as the general population. PRISM may be particularly helpful for improving benefit-finding and hope for those who have experienced TEs.
Literature
8.
go back to reference Lau N, Bradford MC, Steineck A, Scott S, Bona K, Yi-Frazier JP, McCauley E, Rosenberg AR (2019) Examining key sociodemographic characteristics of adolescents and young adults with cancer: a post hoc analysis of the Promoting Resilience in Stress Management randomized clinical trial. Palliat Med 34:026921631988621–026921631988348. https://doi.org/10.1177/0269216319886215CrossRef Lau N, Bradford MC, Steineck A, Scott S, Bona K, Yi-Frazier JP, McCauley E, Rosenberg AR (2019) Examining key sociodemographic characteristics of adolescents and young adults with cancer: a post hoc analysis of the Promoting Resilience in Stress Management randomized clinical trial. Palliat Med 34:026921631988621–026921631988348. https://​doi.​org/​10.​1177/​0269216319886215​CrossRef
15.
go back to reference American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders. Arlington, VA American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders. Arlington, VA
29.
go back to reference Hedström M, Ljungman G, Von Essen L (2005) Perceptions of distress among adolescents recently diagnosed with cancer. J Pediatr Hematol Oncol 27:15–22CrossRefPubMed Hedström M, Ljungman G, Von Essen L (2005) Perceptions of distress among adolescents recently diagnosed with cancer. J Pediatr Hematol Oncol 27:15–22CrossRefPubMed
37.
go back to reference Rutter M (1987) Psychosocial resilience and protective machanisms. Am J Orthop 57:316–331CrossRef Rutter M (1987) Psychosocial resilience and protective machanisms. Am J Orthop 57:316–331CrossRef
Metadata
Title
Adverse childhood experiences (ACEs) and medically traumatic events (TEs) in adolescents and young adults (AYAs) with cancer: a report from the Promoting Resilience in Stress Management (PRISM) randomized controlled trial
Authors
Samantha R. Scott
Alison G. O’Daffer
Miranda C. Bradford
Kaitlyn Fladeboe
Nancy Lau
Angela Steineck
Mallory Taylor
Joyce P. Yi-Frazier
Abby R. Rosenberg
Publication date
01-07-2021
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 7/2021
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-020-05888-x

Other articles of this Issue 7/2021

Supportive Care in Cancer 7/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine